Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Chronic Pruritus: Bedside to Bench Perspectives
Description
The transcript discusses the intricate relationship between the microbiome, particularly Staphylococcus aureus, and chronic pruritus (itching) in dermatological conditions such as atopic dermatitis and prurigo nodularis. It highlights how the microbiome, often overlooked in dermatology, is crucial for understanding and potentially treating chronic itch. The session explains that itch is a dynamic process involving immune cells, nerves, and microbial interactions, where Staphylococcus aureus can exacerbate inflammation and worsen itch through various mechanisms such as protease activity and neuroimmune interactions. In atopic dermatitis, barrier dysfunction allows Staphylococcus aureus to thrive, leading to persistent inflammation and itch. Emerging research suggests that targeted treatments like dupilumab can reduce Staphylococcus colonization, improve skin barrier function, and potentially reshape the microbiome. The talk emphasizes the need for microbiome-friendly therapies and highlights promising strategies like bacteriophage therapy and quorum-sensing inhibition to manage microbial imbalances without disrupting the overall skin ecology. The presenter calls for increased research to understand these interactions and their implications for developing effective therapies for chronic itch.
View moreConclusions
- The skin microbiome significantly impacts itch pathophysiology in conditions such as atopic dermatitis (AD) and prurigo nodularis (PN).
- Staphylococcus aureus (S. aureus) not only colonizes the skin but actively drives itch and inflammation through neuroimmune activation and barrier disruption.
- Barrier dysfunction due to changes in skin pH and protease activity facilitates S. aureus overgrowth, perpetuating chronic itching.
- Dupilumab treatment reduces S. aureus colonization and correlates with improvements in skin barrier function and reduction in itch intensity.
- Prurigo nodularis is characterized by a self-perpetuating cycle of inflammation, fibrosis, and neuroimmune activation distinct from atopic dermatitis.
- Microbial dysbiosis is a modifiable factor that influences chronic itch, suggesting opportunities for microbiome-friendly therapies.
- Current decolonization strategies, such as topical antibiotics, may exacerbate dysbiosis and are not consistently effective in reducing persistent S. aureus colonization.
- Innovative approaches, including probiotics and bacteriophage therapy, offer potential strategies for managing itch without disrupting the entire skin microbiome.
- Kenney HM et al. J Allergy Clin Immunol. Feb 2025.
- Kline, S, Saito, Y & Archer, N. DNA and Cell Biology July 2024.
- Biazus Soares G, Hashimoto T, Yosipovitch G. J Invest Dermatol. May 2024.
- R. Talpur M, R. Bassett, M. Duvic. Comparative Study > Clin Cancer Res. 2014 Aug 15;20(16):4339-48.
- Andreas Willerslev-Olsen et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.
- Zeng Z, Vadivel CK, Gluud M, et al. J Invest Dermatol. Dec 2024.
- Piewngam P, Otto M. Lancet Microbe. 2024.